NHS logo
Coronary heart disease (CHD) is the world’s number one killer, accounting for 15% of UK deaths in 2019¹. HeartFlow FFRCT analysis provides clinicians with a more efficient pathway for diagnosing CHD that combines simulation models and medical imaging data.
Previously, diagnosis of CHD was determined primarily by coronary angiography, an invasive and costly procedure. To avoid risks from cardiac catheterisation, many healthcare systems rely on stress testing as a gatekeeper for coronary angiography, but stress tests do not always deliver reliable results and often result in more testing or overuse of invasive procedures such as invasive coronary angiography. HeartFlow FFRCT analysis utilises data from a patient’s non-invasive coronary CT, passing it through powerful computer algorithms to simulate blood flow and assess the impact of blockages on coronary blood flow.
The HIN works with stakeholders including the supplier and clinicians to support with the implementation and adoption of HeartFlow FFRCT analysis in South London. HeartFlow FFRCT analysis is now in use in a number of south London trusts and has been listed on the MedTech Funding Mandate (MTFM) since April 2021.
We will continue to support existing trusts through this transition, whilst also working with newly adopting trusts to initiate use of HeartFlow FFRCT analysis. Please get in touch at hin.nhsaac@nhs.net for further information.
Email the team
There is no excerpt because this is a protected post.
HIN Senior Programme Manager Dom Norton writes about a national programme, called the MedTech Funding Mandate, and the impact it is having on patients in south London.
To mark World Sickle Cell Day HIN project manager Iona de Wet writes about the impact of sickle cell disease on those who have it, and what is being done to improve care. It is difficult to talk about
